Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

Howard West, Michael McCleod(Sarah Cannon), Maen Hussein(Sarah Cannon), Alessandro Morabito(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Achim Rittmeyer, Henry Jacob Conter(William Osler Health System), Hans‐Georg Kopp(Robert Bosch (Germany)), Davey B. Daniel(Tennessee Oncology), Steven McCune(Northwest Behavioral Medicine), Tarek Mekhail(Florida Hospital Cancer Institute), Alona Zer(Rabin Medical Center), Niels Reinmuth(Asklepios Fachkliniken München-Gauting), Ahad A. Sadiq(Fort Wayne Medical Institute), Alan Sandler, Wei Lin(Nektar Therapeutics (United States)), Tania Ochi Lohmann(Roche (Switzerland)), Venice Archer(Roche (United Kingdom)), Lijia Wang, Marcin Kowanetz, Federico Cappuzzo(Azienda Unità Sanitaria Locale Della Romagna)
The Lancet Oncology
May 20, 2019
Cited by 1,663

Abstract


Related Papers

No related papers found

Powered by citation graph analysis